Skip to main content

Gemcitabine News

TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer

THURSDAY, Aug. 21, 2025 – For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical gemcitabine-releasing system, TAR-200 ...

Device Eliminates Bladder Cancers in 4 of 5 Cases

MONDAY, Aug. 18, 2025 — A new implant eliminated bladder cancer in more than 4 out of 5 high-risk cases, new clinical trial results show. The miniature pretzel-shaped device, dubbed TAR-200, slowly r...

FDA Approves Merck’s Keytruda (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

RAHWAY, N.J.--(BUSINESS WIRE) November 1, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...

FDA Medwatch Alert: Injectable Products by Mylan: Recall - Presence of Particulate Matter

including certain lots of: Gemcitabine for Injection Carboplatin Injection Methotrexate Injection Cytarabine Injection See the press release for a listing of the product strength, NDC, and lot...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Ovarian Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Breast Cancer

Gemcitabine patient information at Drugs.com